|
Select Publications:
1.
DePestel
DD, Benninger M, Danziger L, LaPlante KL, May C, Luskin A,
Pichichero M, Hadley JA.
Cephalosporin
Use in the Treatment of Penicillin-Allergic Patients; Status: in
press. Journal of the American Pharmacists Association.
2.
LaPlante KL,
Rybak MJ. Andes D, Craig WA. Community Associated-Methicillin
Resistant Staphylococcus aureus isolates versus Daptomycin,
Clindamycin, Doxycycline, Linezolid and
Trimethoprim/Sulfamethoxazole in an in vitro Pharmacodynamic
model.
Antimicrob Agents Chemother. 2008 Apr 14, Eur ahead of print
3.
LaPlante KL,
Mersfelder TL, Ward KE, Quilliam, BJ.
Prevalence of
and risk factors for dysglycemia in patients receiving gatifloxacin
and levofloxacin in an outpatient setting. Pharmacotherapy. 2008
Jan;28(1):82-9.
4.
Attwood
RJ, LaPlante KL.
Telavancin, a novel lipoglycopeptide antimicrobial agent.
Am J Health Syst
Pharm. 2007 Nov 15;64(22):2335-48.
5.
LaPlante KL
Mermel LA.. In Vitro Activity of Daptomycin and Vancomycin Lock
Solutions on Staphylococcal Biofilms in a Central Venous
Catheter Model.
Nephrol. Dial. Transplant. 22:
2239-2246
6.
LaPlante KL,
Rybak MJ, Tsuji B, Lodise, T, Kaatz GW, Fluoroquinolone Resistance
in Streptococcus pneumoniae, Area Under the
Curve: Minimum Inhibitory Concentration Ratio and the
Probability of Resistance Development with Gatifloxacin,
Gemifloxacin, Levofloxacin, and Moxifloxacin. Antimicrob Agents
Chemother. 2007 Feb 12.
7.
LaPlante KL,
Rybak MJ, Amjad A, Kaatz GW.
Antimicrobial
Susceptibility and Staphylococcal Chromosomal Cassette mec Type in
Community- and Hospital-Associated Methicillin-Resistant
Staphylococcus aureus. Pharmacotherapy. 2007 Jan;27(1):3-10.
8.
LaPlante KL,
In vitro activity of lysostaphin, mupirocin, and tea tree oil
against clinical methicillin-resistant Staphylococcus aureus.
Diagn Microbiol Infect Dis. 2006 Nov 30
9.
Socha A,
LaPlante KL, Rowley DR, New bisanthraquinone antibiotics and
semi-synthetic derivatives with potent activity against clinical
Staphylococcus aureus and Enterococcus faecium isolates. Bioorg Med
Chem. 2006 Dec 15;14(24):8446-54. Epub 2006 Sep 18
10.
LaPlante KL,
Rybak MJ, Leuthner KL, Chin JN Impact of Enterococcus faecalis
on the bactericidal activities of arbekacin, daptomycin, linezolid,
and tigecycline against methicillin-resistant Staphylococcus
aureus in a mixed-pathogen pharmacodynamic model. Antimicrob
Agents Chemother. 2006 Apr;50(4):1298-303.
11.
Ward KE, Mersfelder TL, LaPlante KL.
Oritavancin--an
investigational glycopeptide antibiotic.
Expert Opin Investig Drugs. 2006 Apr;15(4):417-29. Review.
12.
Rybak MJ,
LaPlante KL. Community-associated methicillin-resistant
Staphylococcus aureus: a review. Pharmacotherapy. 2005
Jan;25(1):74-85. Review.
13.
LaPlante KL,
Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the
activities of nafcillin, vancomycin, linezolid, and daptomycin,
alone and in combination with gentamicin, in an in vitro
pharmacodynamic model. Antimicrob Agents Chemother. 2004
Dec;48(12):4665-72.
14.
LaPlante KL,
Rybak, MJ. Daptomycin - a novel antibiotic against Gram-positive
pathogens. Expert Opin Pharmacother. 2004 Nov;5(11):2321-31. Review.
15.
LaPlante KL,
Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested
against arbekacin, daptomycin, and tigecycline. Diagn Microbiol
Infect Dis. 2004 Oct;50(2):125-30.
16.
Tedesco KL,
Rybak MJ. Daptomycin; Drug Review. Pharmacotherapy 2004;24
(1):41-57.
Book Chapter:
LaPlante
KL, Rybak
MJ. Daptomycin; Antimicrobial Therapy and Vaccines Volume II. Second
Edition. V. L. Yu, R. Weber & D. Raoult, Eds. ESun Technologies, ISBN
0-9700027-5-0.
|
